Subtype
Uterine Neoplasm
CI-CAN-00004208Explore in graph →
Non-malignant925 active trials7 approved drugs44 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004208Explore in graph →
Clinical trials
3,823 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06598176 | Developing a Combined Molecular Screening and Triage Test for Cervical Cancer in Self-samples(COMBISCREEN) | recruiting | N/A | 100 | Universiteit AntwerpenOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06582108 | UNDERSTANDING the RAREST GYNECOLOGICAL CANCERS: a MULTI -OMICS PLATFORM for IMPROVED PATIENTS MANAGEMENT(ROAR) | not yet recruiting | — | 190 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER |
| 1 |
| Sep 3, 2024 |
| clinicaltrials |
| NCT06576362 | Evaluation of Ultrasound-guided Transuterine Vaginal Biopsy Technique in Uterine Fibromatous Disease(EFIBIA) | not yet recruiting | N/A | 250 | Assistance Publique Hopitaux De MarseilleOTHER | 0 | Aug 30, 2024 | clinicaltrials |
| NCT06014190 | HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer | recruiting | Phase 2 | 460 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Aug 29, 2024 | clinicaltrials |
| NCT01686126 | Improving the Treatment for Women With Early Stage Cancer of the Uterus(feMMe) | active not recruiting | Phase 2 | 165 | Queensland Centre for Gynaecological CancerOTHER_GOV | 2 | Aug 28, 2024 | clinicaltrials |
| NCT05472311 | Cervical Cancer Elimination -Using Implementation Science to Evaluate Deliver and Cost Introduction of Thermal Ablation(TIBA) | recruiting | N/A | 565 | University of WashingtonOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06557954 | Cervical Cytology DNA Methylation for Cervical Cancer Screening | not yet recruiting | — | 30,000 | Lei LiOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT05235516 | A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer(AK104-305) | active not recruiting | Phase 3 | 636 | AkesoINDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06548763 | Oral Topotecan With Toripalimab for Patients With Endometrial Cancer | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06544720 | SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas | recruiting | Phase 1 | 18 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06541288 | A Prospective Cohort Study Comparing AI Prediction Model With Imaging Assessment to Diagnose Lymph Node Metastasis in Cervical Cancer | not yet recruiting | N/A | 230 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06531486 | A Study of XS-02 Capsules in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 96 | NovaOnco Therapeutics Co., Ltd.INDUSTRY | 0 | Aug 1, 2024 | clinicaltrials |
| NCT05764044 | Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer(AddChemo) | recruiting | Phase 3 | 365 | Hospital do CoracaoOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06509724 | Comparison of Conventional and Hypofractionated IMRT in High-Risk Cervical Cancer Post-Radical Hysterectomy(POHIM-P3) | recruiting | Phase 3 | 248 | Samsung Medical CenterOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT06501417 | EC_ItaLynch: Mainstreaming the Diagnosis of Lynch Syndrome(EC_ItaLynch) | not yet recruiting | — | 600 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 15, 2024 | clinicaltrials |
| NCT06501846 | Pipelle® Under Ultrasound Guidance (PUG) to Investigate Post-menopausal Bleeding.(PUG) | recruiting | N/A | 92 | Imperial College Healthcare NHS TrustOTHER | 1 | Jul 15, 2024 | clinicaltrials |
| NCT03386734 | International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer(SENTICOLIII) | active not recruiting | N/A | 989 | Centre Hospitalier Universitaire de BesanconOTHER | 14 | Jul 8, 2024 | clinicaltrials |
| NCT06475599 | Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer | not yet recruiting | Phase 3 | 420 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 27, 2024 | clinicaltrials |
| NCT03755739 | Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors | recruiting | Phase 2 / Phase 3 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05187338 | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06462378 | Proton Therapy for Locally Advanced Cervical Cancer | recruiting | Phase 2 | 55 | University of AarhusOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT05876130 | Postoperative Hypofractionated Intensity-modulated Radiotherapy Endometrial Cancer | recruiting | N/A | 92 | Samsung Medical CenterOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT04422366 | Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | recruiting | Phase 3 | 8,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
| NCT06442605 | Clinical Research on the Application of Single-channel Uterine Fibroid Morcellation System in Laparoscopic Myomectomy | not yet recruiting | N/A | 22 | First People's Hospital of HangzhouOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06433817 | Spectral CT in Radiotherapy for Cervical Cancer | recruiting | — | 150 | Peking Union Medical College HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT06431100 | a Single-arm, Single-center, Open Clinical Study(GK-01) | recruiting | — | 10 | Beijing Geekgene Technology Co., LTDINDUSTRY | 1 | May 28, 2024 | clinicaltrials |
| NCT06426056 | Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial. | not yet recruiting | Phase 2 | 64 | Peking University Third HospitalOTHER | 0 | May 23, 2024 | clinicaltrials |
| NCT06326294 | Assessment of the Effectiveness of TA Versus LEEP for Cervical Cancer Risk Reduction in WLHIV in Mozambique | recruiting | N/A | 4,844 | Instituto Nacional de Saúde, MozambiqueOTHER_GOV | 1 | May 22, 2024 | clinicaltrials |
| NCT06419673 | Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer | active not recruiting | Phase 2 | 240 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT01511328 | Randomized Implementation of Primary HPV Testing in the Organized Screening for Cervical Cancer in Stockholm | active not recruiting | N/A | 270,000 | Karolinska InstitutetOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06417736 | Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women | recruiting | N/A | 75 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06413992 | Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer | recruiting | Phase 2 | 117 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06251947 | Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen | recruiting | Phase 2 | 83 | Shandong UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT05797831 | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | recruiting | Phase 2 / Phase 3 | 268 | Kartos Therapeutics, Inc.INDUSTRY | 17 | May 2, 2024 | clinicaltrials |
| NCT06391190 | Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer | recruiting | Phase 1 / Phase 2 | 20 | RenJi HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06256224 | Toripalimab Combined With Definitive CCRT for LACC Patients | recruiting | N/A | 150 | Ruijin HospitalOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT05931445 | Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer | active not recruiting | N/A | 500 | Comprehensive Support Project for Oncology ResearchOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT05817214 | Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer | recruiting | Phase 2 | 35 | Zhongnan HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT05027776 | Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years | recruiting | Phase 3 | 1,348 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05371353 | Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine | recruiting | — | 600 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06354738 | Improving Endometrial Cancer Assessment by Combining Genomic Profiling and Surgical Assessment(EUGENIE) | recruiting | N/A | 1,000 | University Hospital, GasthuisbergOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05080556 | Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer(ACTOv) | recruiting | Phase 2 | 80 | University College, LondonOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06358053 | CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers | not yet recruiting | Phase 1 | 24 | Corregene Biotechnology Co., LtdINDUSTRY | 0 | Apr 10, 2024 | clinicaltrials |
| NCT05186493 | Laparoscopic Robot-assisted Pelvic Exenteration for Pelvic Primary and Recurrent Cancers | recruiting | N/A | 40 | Oslo University HospitalOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT01820858 | The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma(EC-01) | active not recruiting | Phase 3 | 300 | Ding MaOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT01820884 | The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma(EC-02) | active not recruiting | N/A | 240 | Ding MaOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06333821 | A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma | not yet recruiting | Phase 3 | 460 | Biotech Pharmaceutical Co., Ltd.OTHER | 0 | Mar 27, 2024 | clinicaltrials |
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06297811 | Myeloprotection With Trilaciclib in Pan-cancer Population | not yet recruiting | Phase 2 | 132 | Sun Yat-sen UniversityOTHER | 1 | Mar 7, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Sep 19, 2024source: clinicaltrials